CN105194677A - Lactose celecoxib medicine composition - Google Patents
Lactose celecoxib medicine composition Download PDFInfo
- Publication number
- CN105194677A CN105194677A CN201410284127.0A CN201410284127A CN105194677A CN 105194677 A CN105194677 A CN 105194677A CN 201410284127 A CN201410284127 A CN 201410284127A CN 105194677 A CN105194677 A CN 105194677A
- Authority
- CN
- China
- Prior art keywords
- celecoxib
- lactose
- solid dispersion
- compositions
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of pharmacy, and relates to a lactose celecoxib medicine composition and a preparation method. The lactose celecoxib medicine composition and the preparation method are characterized in that solid dispersion is formed by lactose celecoxib through a melting method.
Description
Technical field
The invention belongs to pharmaceutical field, relate to a kind of pharmaceutical composition and preparation method of lactose celecoxib, it is characterized in that lactose celecoxib forms solid dispersion by fusion method.
Background technology
Celecoxib (Celecoxib) is a kind of II type cyclooxygenase (COX-2) inhibitor, and alternative acts on II type cyclooxygenase, is widely used in the treatment of osteoarthritis and rheumatoid arthritis clinically.
Patent CN99802185.7 discloses this compound and dissolves hardly in water, this material also has some other obvious character feature, be needle-like as tied its crystallization, bring the characteristics such as its caking property, low bulk density and low compressibility thus, these all determine that the poor fluidity of such celecoxib, compressibility are poor, and not easily pulverize as less granule.
In order to solve the indissoluble of medicine, the problems such as crystal formation, research worker can go to attempt solving by preparations etc. such as solid dispersion, but because solid dispersion medicine is highly dispersed in a kind of disperse system existed in solid form formed in solid carrier, be similar to crystallization, its internal structure, larger uncertainty can be there is in physicochemical property, same drug and different auxiliary material, same drug is with adjuvant but ratio is different, preparation method kind difference (fusion method, solvent method, solvent-spraying (freezing) seasoning, solvent-antisolvent method) the identical same drug of ratio and adjuvant, all may produce larger impact to the structure of solid dispersion, thus draw the diverse product of physicochemical property.
Fusion method refers to medicine and carrier material mixing melting, then is cooled to rapidly solid and get final product.
Solvent method is first dissolved in medicine and carrier material in organic solvent, then boils off solvent altogether medicine and carrier material to be separated out simultaneously, finally by being drying to obtain.
Solvent-spraying (freezing) seasoning first medicine and carrier material is dissolved in altogether in solvent, and then spraying or lyophilization, eliminate solvent and get final product.
Solvent-antisolvent method first medicine and carrier material is dissolved in altogether in solvent, then passes into solvent resistant (antisolvent generally selects supercritical fluid) and make medicine and carrier material separate out simultaneously and get final product.
Patent application CN102000018A discloses a kind of Celecoxib solid dispersion and preparation method thereof, be prepared into preparation according to a conventional method again after Polyethylene Glycol celecoxib crude drug and molecular weight being greater than 4000 adopts fusion method to be prepared into solid dispersion, overcome the deficiency that celecoxib crude drug difficulty is pulverized.But the method preparation temperature is high, the Polyethylene Glycol viscosity of melting is comparatively large, and celecoxib material dissolution is slow, and not easily uniform dissolution, operation easier is large.
Patent application CN102988296 discloses the solid dispersion containing celecoxib and carrier material, described carrier material is selected from one or more in polyvinylpyrrolidone, copolyvidone, polyvinylpolypyrrolidone, and in solid dispersion, the weight ratio of carrier material and celecoxib can be low to moderate 0.2: 1.Its preparation method is jointly dissolved in organic solvent carrier material and celecoxib, or carrier material suspendible is dispersed in the organic solvent of celecoxib, adopt drying under reduced pressure or spray-dired mode to remove organic solvent and namely obtain solid dispersion, this solid dispersion can be prepared into various solid preparation after pulverizing.But the elasticity of this solid dispersion is comparatively large, not easily pulverize as microgranule.
Summary of the invention
Below will the invention will be further described by embodiment, these descriptions are not be further limited content of the present invention.One skilled in the art will understand that the equivalent replacement that technical characteristic of the present invention is done, or improve accordingly, still belong within protection scope of the present invention.
The invention provides a kind of pharmaceutical composition and the preparation method that contain lactose celecoxib, feature is celecoxib, lactose forms solid dispersion by fusion method, this solid dispersion has the advantages that to be easy to be ground into microgranule, with solid orally ingestible prepared by this kind of microgranule, there is more good dispersive property and dissolution, thus can human bioavailability be improved.
The present invention also provides the preparation method of the solid dispersion containing celecoxib, lactose, simple to operate, and in the lactose of melting, celecoxib material dissolution is comparatively rapid, is easy to dispersion, is very applicable to suitability for industrialized production.This is mainly because the fusing point of lactose, far above the fusing point of celecoxib, adds celecoxib after lactose melting, and celecoxib can melting rapidly, can realize being uniformly dispersed rapidly by modes such as such as ultrasound wave, thus the quality of guarantee solid dispersion.
Lactose is as the higher adjuvant of a kind of fusing point, prepared in solid dispersion by fusion method and often cause decomposition or coking, cannot carry out, so do not have lactose to prepare the report of solid dispersion in document, and by pressurization, its fusing point is declined in the present invention, avoid the appearance of the problems referred to above, start the method preparing lactose type solid dispersion.
A kind of pharmaceutical composition, it is characterized in that active component is celecoxib, excipient substance is one or more in lactose and sodium lauryl sulphate, polyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, magnesium stearate, and wherein celecoxib and lactose form solid dispersion.Above-mentioned composition, it is characterized in that celecoxib lactose solids dispersion preparation method is extremely melted at 8-10 atmospheric heated under pressure by solid water-free lactose, add celecoxib, dissolve to obtain settled solution, on the steel plate being poured on room temperature, cooling, fully after solidification, obtains celecoxib lactose solids dispersion fast.
Above-mentioned compositions, is characterized in that celecoxib, lactose and sodium lauryl sulphate form solid dispersion.Above-mentioned composition, it is characterized in that being that solid water-free lactose extremely melts at 8-10 atmospheric heated under pressure by the preparation method of celecoxib lactose sodium lauryl sulphate solid dispersion, add sodium lauryl sulphate, celecoxib, dissolve to obtain settled solution, on the steel plate being poured on room temperature, cooling, fully after solidification, obtains celecoxib lactose sodium lauryl sulphate solid dispersion fast.
Above-mentioned compositions, its feature is lactose, sodium lauryl sulphate, polyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose and magnesium stearate at excipient substance.Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and sodium lauryl sulphate in solid dispersion is 1:0.01-0.15.Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and sodium lauryl sulphate in solid dispersion is 1:0.01-0.1.Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and sodium lauryl sulphate in solid dispersion is 1:0.01-0.05.
Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and lactose in solid dispersion is 1:0.2-1.0.
Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and lactose in solid dispersion is 1:0.3-0.8.
Above-mentioned compositions, is characterized in that the weight ratio of celecoxib and lactose in solid dispersion is 1:0.3-0.6.
Above-mentioned compositions, is characterized in that the content of polyvinylpyrrolidone is 0.5-6wt%, and the content of cross-linking sodium carboxymethyl cellulose is 0.75-15wt%, and the content of sodium lauryl sulphate is 0-5wt%, and the content of magnesium stearate is 0.1-5wt%.
Above-mentioned compositions, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 50%.
Above-mentioned compositions, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 80%.
Above-mentioned compositions, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 90%.
Above-mentioned compositions, is characterized in that preparation type is solid orally ingestible.Above-mentioned compositions, is characterized in that solid orally ingestible is the one in capsule, tablet, granule, powder.
Above-mentioned compositions, is characterized in that lactose is Lactis Anhydrous.
A kind of solid dispersion be made up of celecoxib and lactose.
A kind of solid dispersion be made up of celecoxib, lactose, sodium lauryl sulphate.
Detailed description of the invention
Below will the invention will be further described by embodiment, these descriptions are not be further limited content of the present invention.One skilled in the art will understand that the equivalent replacement that technical characteristic of the present invention is done, or improve accordingly, still belong within protection scope of the present invention.
Particle diameter corresponding when D90 particle diameter refers to that the cumulative particle sizes distribution number of a sample reaches 90%.Its physical significance is that the granule that particle diameter is less than it accounts for 90%.
Embodiment 1
By solid water-free lactose at 8-10 atmospheric heated under pressure to melting, add celecoxib, dissolve to obtain settled solution, on the steel plate being poured on room temperature, cooling, fully after solidification, obtains celecoxib lactose solids dispersion fast.The ratio of Lactis Anhydrous, celecoxib sees the following form.Lactis Anhydrous, Celecoxib solid dispersion cross No. two sieves after simple pulverizing, D90 particle diameter is measured with laser particle analyzer, undertaken 2 times by jet mill again to pulverize, grinding time is 10 minutes/time, measure the D90 particle diameter of powder with laser particle analyzer more afterwards, both subtract each other and show that D90 particle diameter is poor.
| Embodiment number | Celecoxib (g) | Lactis Anhydrous (g) | D90 particle diameter difference (μm) |
| 1-1 | 100 | 100 | 624 |
| 1-2 | 100 | 80 | 661 |
| 1-3 | 100 | 60 | 706 |
| 1-4 | 100 | 30 | 698 |
| 1-5 | 100 | 20 | 665 |
The fusing point of embodiment 1-1 to 1-5 is between 182-195 DEG C.
Embodiment 2
By solid water-free lactose at 8-10 atmospheric heated under pressure to melting, add sodium lauryl sulphate, celecoxib, dissolve to obtain settled solution, on the steel plate being poured on room temperature, cooling, fully after solidification, obtains celecoxib lactose solids dispersion fast.The ratio of Lactis Anhydrous, celecoxib sees the following form.The solid dispersion of sodium lauryl sulphate, Lactis Anhydrous, celecoxib crosses No. two sieves after simple pulverizing, D90 particle diameter is measured with laser particle analyzer, undertaken 2 times by jet mill again to pulverize, grinding time is 10 minutes/time, measure the D90 particle diameter of powder with laser particle analyzer more afterwards, both subtract each other and show that D90 particle diameter is poor.
The fusing point of embodiment 2-1 to 2-5 is between 176-186 DEG C.
Embodiment 3
By solid water-free lactose at 8-10 atmospheric heated under pressure to melting, add celecoxib, dissolve to obtain settled solution, on the steel plate being poured on room temperature, cooling, fully after solidification, obtains celecoxib lactose solids dispersion fast.The ratio of Lactis Anhydrous, celecoxib sees the following form.Lactis Anhydrous, Celecoxib solid dispersion cross No. two sieves after simple pulverizing, D90 particle diameter is measured with laser particle analyzer, undertaken 2 times by jet mill again to pulverize, grinding time is 10 minutes/time, measure the D90 particle diameter of powder with laser particle analyzer more afterwards, both subtract each other and show that D90 particle diameter is poor.
| Embodiment number | Celecoxib (g) | Lactis Anhydrous (g) | D90 particle diameter difference (μm) |
| 3-1 | 100 | 110 | 577 |
| 3-2 | 100 | 150 | 526 |
| 3-3 | 100 | 200 | 531 |
| 3-4 | 100 | 500 | 544 |
| 3-5 | 100 | 1000 | 557 |
| 3-6 | 100 | 10 | 529 |
The fusing point of embodiment 3-1 to 3-5 is between 186-194 DEG C.
Comparative examples 1
According to the method corresponding preparation comparative examples 2-1 to 2-3 of embodiment 1-3 in invention CN102000018B.
The particle diameter measured before and after solid dispersion comminution by gas stream according to the method for embodiment 1 is poor.
Comparative examples 2
Corresponding comparative examples 2-1 to 2-5 is prepared according to solid dispersion Example formulations 2,6,10,14,19 in invention CN102988296A.The particle diameter measured before and after solid dispersion comminution by gas stream according to the method for embodiment 1 is poor.
Comparative examples 3
According to the crystallization that the preparation method of celecoxib in invention CN1141630A obtains, the particle diameter measured before and after solid dispersion comminution by gas stream according to the method for embodiment 1 is poor.
| Comparative examples number | Celecoxib (g) | D90 particle diameter difference (μm) |
| 3 | 100 | 326 |
By embodiment 1,2,3, the data of comparative examples 1,2,3, can illustrate compared with other solid dispersion, solid dispersion containing lactose, celecoxib composition is more the microgranule that particle diameter is less with pulverizing, and add the lactose of sodium lauryl sulphate, celecoxib composition the crushing effect that do not add of solid dispersion better, and the crushing effect of the solid dispersion made when being equal to or less than active component celecoxib with the weight of standard empirical adjuvant lactose is by contrast better.
Example of formulations 1
Prescription (unit be gram):
The solid dispersion that embodiment obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, mix with microcrystalline Cellulose, lactose, cross-linking sodium carboxymethyl cellulose, sodium lauryl sulphate, starch with polyvinylpyrrolidone, wet granulation, dry, add magnesium stearate, be distributed into capsule, obtain the capsule containing celecoxib 100mg.
Example of formulations 2
Prescription (unit be gram):
The solid dispersion that embodiment obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, measure crosslinked carboxymethyl fecula sodium with lactose, microcrystalline Cellulose, half, sodium lauryl sulphate mixes, starch with polyvinylpyrrolidone, granulate, dry, add magnesium stearate and another half amount crosslinked carboxymethyl fecula sodium mixing, tabletted is heavily the fusiformis element sheet of 500mg, with Opadry white coating material coating, must containing the coated tablet of celecoxib 100mg.
Example of formulations 3
Prescription (unit be gram):
The solid dispersion that embodiment obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, mix with microcrystalline Cellulose, lactose, cross-linking sodium carboxymethyl cellulose, sodium lauryl sulphate, starch with polyvinylpyrrolidone, wet granulation, dry, add magnesium stearate, be distributed into capsule, obtain the capsule containing celecoxib 100mg.
Example of formulations 4
Prescription (unit be gram):
The solid dispersion that comparative examples obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, measure crosslinked carboxymethyl fecula sodium with lactose, microcrystalline Cellulose, half, sodium lauryl sulphate mixes, starch with polyvinylpyrrolidone, granulate, dry, add magnesium stearate and another half amount crosslinked carboxymethyl fecula sodium mixing, tabletted is heavily the fusiformis element sheet of 500mg, with Opadry white coating material coating, must containing the coated tablet of celecoxib 100mg.
Control formulation embodiment 1
Prescription (unit be gram):
The solid dispersion that embodiment obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, mix with microcrystalline Cellulose, lactose, cross-linking sodium carboxymethyl cellulose, sodium lauryl sulphate, starch with polyvinylpyrrolidone, wet granulation, dry, add magnesium stearate, be distributed into capsule, obtain the capsule containing celecoxib 100mg.
Control formulation embodiment 2
Prescription (unit be gram):
The solid dispersion that comparative examples obtained is pulverized as D90 is the microgranule of 20 ± 2 μm, measure crosslinked carboxymethyl fecula sodium with lactose, microcrystalline Cellulose, half, sodium lauryl sulphate mixes, starch with polyvinylpyrrolidone, granulate, dry, add magnesium stearate and another half amount crosslinked carboxymethyl fecula sodium mixing, tabletted is heavily the fusiformis element sheet of 500mg, with Opadry white coating material coating, must containing the coated tablet of celecoxib 100mg.
Control formulation embodiment 3
Celecoxib, lactose are pulverized as D90 is the microgranule of 20 ± 2 μm, mix with microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, sodium lauryl sulphate, starch with polyvinylpyrrolidone, wet granulation, dry, add magnesium stearate, be distributed into capsule, obtain the capsule containing celecoxib 100mg.
Pharmacological Examples:
Dissolution test: according to the dissolution of the pharmaceutical preparation that first method (basket method) the method mensuration example of formulations in 2010 editions Chinese Pharmacopoeia annex XC dissolution methods, control formulation embodiment obtain, with simulated gastric fluid 1000ml for dissolution medium, rotating speed is 50 turns of rain, operate in accordance with the law, get solution during 45min appropriate, filter, to measure subsequent filtrate appropriate for precision respectively, the solution about containing 0.1mg celecoxib in every 1ml is become, as need testing solution with mobile phase dissolved dilution; Separately get celecoxib reference substance appropriate, add mobile phase dissolved dilution and make the solution of every 1ml containing 0.1mg, solution in contrast, measure in accordance with the law, the stripping quantity of celecoxib in calculating every, calculate the dissolution of average dissolution as embodiment, limit all should be 75% of labelled amount.
Claims (10)
1.
oneplant pharmaceutical composition, it is characterized in that active component is celecoxib, excipient substance contains one or more in lactose, sodium lauryl sulphate, polyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, magnesium stearate, and wherein celecoxib and lactose form solid dispersion.
2. compositions as claimed in claim 1, is characterized in that the weight ratio of celecoxib and lactose in solid dispersion is 1:0.2-1.0.
3. compositions as claimed in claim 1, it is characterized in that the content of polyvinylpyrrolidone is 0.5-6wt%, the content of cross-linking sodium carboxymethyl cellulose is 0.75-15wt%, and the content of sodium lauryl sulphate is 0-5wt%, and the content of magnesium stearate is 0.1-5wt%.
4. the compositions as described in claim 1,2, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 50%.
5. the compositions as described in claim 1,2, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 80%.
6. the compositions as described in claim 1,2, is characterized in that forming solid dispersion weight ratio in the composition by celecoxib and lactose is not less than 90%.
7. the compositions as described in claim 1,2, is characterized in that preparation type is solid orally ingestible.
8. compositions as claimed in claim 7, is characterized in that solid orally ingestible is the one in capsule, tablet, granule, powder.
9. the compositions as described in claim 1,2, is characterized in that lactose is Lactis Anhydrous.
10. celecoxib according to claim 1 and lactose form a solid dispersion, it is characterized in that solid lactose to melt in a heated condition, add celecoxib, dissolve and obtain settled solution, obtain solid dispersion after then cooling fast.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410284127.0A CN105194677A (en) | 2014-06-23 | 2014-06-23 | Lactose celecoxib medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410284127.0A CN105194677A (en) | 2014-06-23 | 2014-06-23 | Lactose celecoxib medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105194677A true CN105194677A (en) | 2015-12-30 |
Family
ID=54942850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410284127.0A Pending CN105194677A (en) | 2014-06-23 | 2014-06-23 | Lactose celecoxib medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105194677A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604722A (en) * | 2019-09-19 | 2019-12-24 | 山东创新药物研发有限公司 | Solid dispersion method of celecoxib and preparation method of celecoxib capsules |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000018A (en) * | 2010-02-09 | 2011-04-06 | 浙江大学宁波理工学院 | Solid dispersion containing celecoxib as well as preparation method and application thereof |
| CN102793706A (en) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | Preparation method of tolvaptan solid dispersion |
| CN103585164A (en) * | 2013-11-08 | 2014-02-19 | 海南合瑞制药股份有限公司 | Celecoxib solid composition with increased dissolution rate, and preparation method and application thereof |
| CN103932977A (en) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | Preparation method of celecoxib preparation |
| CN104168891A (en) * | 2012-03-02 | 2014-11-26 | 安斯泰来制药株式会社 | Rapidly disintegrating tablet |
-
2014
- 2014-06-23 CN CN201410284127.0A patent/CN105194677A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000018A (en) * | 2010-02-09 | 2011-04-06 | 浙江大学宁波理工学院 | Solid dispersion containing celecoxib as well as preparation method and application thereof |
| CN104168891A (en) * | 2012-03-02 | 2014-11-26 | 安斯泰来制药株式会社 | Rapidly disintegrating tablet |
| CN102793706A (en) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | Preparation method of tolvaptan solid dispersion |
| CN103585164A (en) * | 2013-11-08 | 2014-02-19 | 海南合瑞制药股份有限公司 | Celecoxib solid composition with increased dissolution rate, and preparation method and application thereof |
| CN103932977A (en) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | Preparation method of celecoxib preparation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110604722A (en) * | 2019-09-19 | 2019-12-24 | 山东创新药物研发有限公司 | Solid dispersion method of celecoxib and preparation method of celecoxib capsules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Micronization of atorvastatin calcium by antisolvent precipitation process | |
| KR20120101439A (en) | Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof | |
| CN105168137A (en) | Lactose celecoxib pharmaceutical composition | |
| CN106963741A (en) | Pharmaceutical preparation containing Phenylalamine derivatives | |
| Jain et al. | Development and in vitro evaluation of ibuprofen mouth dissolving tablets using solid dispersion technique | |
| CN104721142A (en) | Rivaroxaban solid dispersion and preparation method thereof | |
| CN102000018B (en) | Solid dispersion containing celecoxib as well as preparation method and application thereof | |
| JP7245637B2 (en) | Method for producing aloe extract | |
| KR20190005939A (en) | Method for producing acetaminophen formulations | |
| CN103705510A (en) | Method for preparing azilsartan solid composition | |
| CN110292575A (en) | Pharmaceutical composition | |
| CN106551946B (en) | Pharmaceutical composition containing trifluorothymidine and tipyrimidine hydrochloride and preparation method thereof | |
| CN105106968A (en) | Gastric-soluble film coating premix and method for preparing same | |
| CN102949402A (en) | Celecoxib composition, and preparation method and use thereof | |
| CN105193727A (en) | Lactose celecoxib solid dispersion composition adopting coprecipitation method | |
| CN105194677A (en) | Lactose celecoxib medicine composition | |
| CN105287384A (en) | Lactose celecoxib solid dispersoid combination prepared through fusion method | |
| TWI724534B (en) | Cellulose powder, lozenges and methods for manufacturing lozenges | |
| CN102294033B (en) | Production process of spherical lactose particle | |
| Han et al. | Mechanistic insight into gel formation of co-amorphous resveratrol and piperine during dissolution process | |
| CN108578370A (en) | Lutein/lutein ester particle and preparation method thereof | |
| CN109953969A (en) | A kind of preparation method of valsartan amlodipine piece | |
| WO2014017507A1 (en) | Solid pharmaceutical preparation | |
| CN107875137B (en) | Traditional Chinese medicine moisture-proof coating agent | |
| CN102600475B (en) | Pharmaceutical pellet cores and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151230 |
|
| RJ01 | Rejection of invention patent application after publication |